MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319682 | Name: Sarecycline HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sarecycline, also known as WC-3035 and P005672, is a novel, tetracycline-derived, narrow-spectrum antibiotic being developed for use as an oral once daily antibiotic treatment for patients suffering from moderate to severe acne vulgaris. Sarecycline was designed by Paratek as a narrow-spectrum antibiotic with anti-inflammatory activity and the potential for a favorable tolerability profile.

Chemical Structure

Sarecycline HCl
Sarecycline HCl
CAS#1035979-44-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 319682

Name: Sarecycline HCl

CAS#: 1035979-44-2 (HCl)

Chemical Formula: C24H30ClN3O8

Exact Mass: 0.0000

Molecular Weight: 523.97

Elemental Analysis: C, 55.02; H, 5.77; Cl, 6.77; N, 8.02; O, 24.43

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,850.00 2 Weeks
2g USD 6,250.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1035979-44-2 (HCl) 1035654-66-0 (free base)
Synonym
WC-3035; WC 3035; WC3035; P005672; P-005672; P 005672; P005672 HCl; Sarecycline hydrochloride; Seysara
IUPAC/Chemical Name
(4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-((methoxy(methyl)amino)methyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride
InChi Key
APPRLAGZQKOUFL-FIPJBXKNSA-N
InChi Code
InChI=1S/C24H29N3O8.ClH/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33;/h5-6,11,13,18,28,30-31,34H,7-9H2,1-4H3,(H2,25,33);1H/t11-,13-,18-,24-;/m0./s1
SMILES Code
O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C=CC(CN(OC)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N.[H]Cl
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Sarecycline HCl interferes with tRNA accommodation and tethers mRNA to the 70S ribosome.
In vitro activity:
In three in vitro models of the human colon, sarecycline had minimal and transient impact on the gut microbiota composition and diversity, when compared to minocycline and doxycycline. Sarecycline caused a slight decline in bacterial diversity at the start of treatment, but abundances of most families remained stable during treatment. All populations recovered to pre-antibiotic levels after sarecycline exposure. These results suggest that sarecycline has minimal off-target effects and negative gastrointestinal sequelae. Reference: Front Microbiol. 2022 May 31;13:901911. https://pubmed.ncbi.nlm.nih.gov/35711781/
In vivo activity:
Sarecycline, compared with other tetracyclines, has low rates of vestibular-related adverse events. In rats, sarecycline was not detected in brain samples postdosing. In the octanol/water solvent system, sarecycline had a numerically lower lipophilicity profile than minocycline and doxycycline at pH 5.5 and 7.4. Reference: Front Med (Lausanne). 2022 Dec 8;9:1033980. https://pubmed.ncbi.nlm.nih.gov/36569144/
Solvent mg/mL mM
Solubility
DMSO 100.0 190.85
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 523.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Moura IB, Grada A, Spittal W, Clark E, Ewin D, Altringham J, Fumero E, Wilcox MH, Buckley AM. Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota. Front Microbiol. 2022 May 31;13:901911. doi: 10.3389/fmicb.2022.901911. PMID: 35711781; PMCID: PMC9194605. 2. Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics (Basel). 2022 Feb 28;11(3):324. doi: 10.3390/antibiotics11030324. PMID: 35326788; PMCID: PMC8944611. 3. Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Front Med (Lausanne). 2022 Dec 8;9:1033980. doi: 10.3389/fmed.2022.1033980. PMID: 36569144; PMCID: PMC9773825. 4. Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01297-18. doi: 10.1128/AAC.01297-18. PMID: 30397052; PMCID: PMC6325184.
In vitro protocol:
1. Moura IB, Grada A, Spittal W, Clark E, Ewin D, Altringham J, Fumero E, Wilcox MH, Buckley AM. Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota. Front Microbiol. 2022 May 31;13:901911. doi: 10.3389/fmicb.2022.901911. PMID: 35711781; PMCID: PMC9194605. 2. Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics (Basel). 2022 Feb 28;11(3):324. doi: 10.3390/antibiotics11030324. PMID: 35326788; PMCID: PMC8944611.
In vivo protocol:
1. Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Front Med (Lausanne). 2022 Dec 8;9:1033980. doi: 10.3389/fmed.2022.1033980. PMID: 36569144; PMCID: PMC9773825. 2. Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01297-18. doi: 10.1128/AAC.01297-18. PMID: 30397052; PMCID: PMC6325184.
1: Kaul G, Saxena D, Dasgupta A, Chopra S. Sarecycline hydrochloride for the treatment of acne vulgaris. Drugs Today (Barc). 2019 Oct;55(10):615-625. doi: 10.1358/dot.2019.55.10.3045040. Review. PubMed PMID: 31720559. 2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548293/ PubMed PMID: 31643616. 3: Hussar DA, Chahine EB. Omadacycline tosylate, Sarecycline hydrochloride, Rifamycin sodium, and Moxidectin. J Am Pharm Assoc (2003). 2019 Sep - Oct;59(5):756-760. doi: 10.1016/j.japh.2019.07.016. PubMed PMID: 31522740. 4: Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019 Sep;14:1235-1242. doi: 10.2217/fmb-2019-0199. Epub 2019 Sep 2. PubMed PMID: 31475868; PubMed Central PMCID: PMC6802708. 5: Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline Review. Ann Pharmacother. 2019 Aug 28:1060028019873111. doi: 10.1177/1060028019873111. [Epub ahead of print] PubMed PMID: 31462063. 6: Deeks ED. Correction to: Sarecycline: First Global Approval. Drugs. 2019 May;79(7):795. doi: 10.1007/s40265-019-01122-z. PubMed PMID: 31037601; PubMed Central PMCID: PMC6520308. 7: Sarecycline (Seysara) - another oral tetracycline for acne. Med Lett Drugs Ther. 2019 Mar 25;61(1568):43-44. Review. PubMed PMID: 31022156. 8: Deeks ED. Sarecycline: First Global Approval. Drugs. 2019 Feb;79(3):325-329. doi: 10.1007/s40265-019-1053-4. Review. Erratum in: Drugs. 2019 Apr 29;:. PubMed PMID: 30659422; PubMed Central PMCID: PMC6505496. 9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK535605/ PubMed PMID: 30601614. 10: Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan. PubMed PMID: 30397052; PubMed Central PMCID: PMC6325184. 11: Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. PubMed PMID: 30235387. 12: Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. J Drugs Dermatol. 2018 Mar 1;17(3):333-338. PubMed PMID: 29537451.